Turning Point Therapeutics (NASDAQ:TPTX) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.
Valuation & Earnings
This table compares Turning Point Therapeutics and Prothena's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Turning Point Therapeutics | N/A | N/A | $-72,130,000.00 | ($2.99) | -23.84 |
Prothena | $810,000.00 | 1,136.96 | $-77,680,000.00 | ($1.95) | -11.81 |
Turning Point Therapeutics has higher earnings, but lower revenue than Prothena. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Turning Point Therapeutics and Prothena's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Turning Point Therapeutics | N/A | -23.81% | -23.08% |
Prothena | -13,615.75% | -41.97% | -26.26% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Turning Point Therapeutics and Prothena, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Turning Point Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
Prothena | 0 | 0 | 7 | 0 | 3.00 |
Turning Point Therapeutics currently has a consensus target price of $153.7143, suggesting a potential upside of 117.85%. Prothena has a consensus target price of $29.4286, suggesting a potential upside of 30.85%. Given Turning Point Therapeutics' higher possible upside, equities research analysts clearly believe Turning Point Therapeutics is more favorable than Prothena.
Insider and Institutional Ownership
81.3% of Turning Point Therapeutics shares are held by institutional investors. Comparatively, 90.2% of Prothena shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by company insiders. Comparatively, 30.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Turning Point Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Prothena has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.
Summary
Prothena beats Turning Point Therapeutics on 6 of the 11 factors compared between the two stocks.